A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants With Prior Myocardial Infarction Who Have Elevated Coronary Inflammation Based on FAI Score Assessed by CCTA

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is:
Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA
Researchers will compare the effects with placebo group after 6 months of treatment
Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Start Date15 Jun 2025

Sponsor / Collaborator

Abcentra LLC

NCT01727778

/ CompletedPhase 1

Open-label, Single-centre, Phase I, Multi-dose Escalating Study to Investigate the Safety and Preliminary Efficacy of an i.v. Infusion of the Anti-GRP78 Monoclonal IgM Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Primary
- To evaluate the safety and tolerability of escalating doses of an intravenous (i.v.) infusion of PAT-SM6 in subjects with relapsed or refractory multiple myeloma.
Secondary
To evaluate the efficacy and pharmacodynamics by analysis of serum and urine M protein, serum free light chains (FLC) κFLC and λFLC, total immunoglobulins, β2-microglobulin, C-reactive protein (CRP), exploratory biomarkers and anti-PAT-SM6 antibodies.
To evaluate the duration of response and the progression free survival.

Start Date01 Oct 2012

Sponsor / Collaborator

Patrys Ltd.

NCT01486823

/ CompletedPhase 1

An Open-label, Single-dose Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

This is a study in healthy volunteers designed to investigate the PK following intravenous and subcutaneous administration of MLDL1278A (also known as BI-204). The bioavalialbility of MLDL1278A after subcutaneous administration will be determined.

Start Date01 Nov 2011

Sponsor / Collaborator

BioInvent International AB

[+1]

100 Clinical Results associated with Low-density lipoprotein

100 Translational Medicine associated with Low-density lipoprotein

0 Patents (Medical) associated with Low-density lipoprotein

2,515

Literatures (Medical) associated with Low-density lipoprotein

01 Oct 2025·Bioelectrochemistry

A high-sensitivity label-free electrochemical aptasensor for point-of-care measurements of low-density lipoprotein in plasma based on aptamer and MXene-CMCS-Hemin nanocomposites

Article

Author: Gong, Junyan ; Liang, Jintao ; Dong, Shuaikang ; Li, Guiyin ; Tan, Xiaohong ; Zhou, Zhide ; Chen, Xuyang

Cardiovascular disease (CVD) remains a significant worldwide health challenge, with mortality rates rising rapidly. Low-density lipoprotein (LDL) is a crucial serum biomarker for the early diagnosis of CVD, which can significantly improve outcomes and reduce mortality. Herein, a label-free electrochemical aptasensor for rapid detection of LDL was developed based on the titanium carbide-carboxymethyl chitosan-hemin (MXene-CMCS-Hemin) nanocomposites as the electrochemical signal probe. Firstly, gold nanoparticles (Au NPs) were electrodeposited onto a screen-printed carbon electrode (SPCE) to form a conductive substrate. Subsequently, the MXene-CMCS-Hemin nanocomposites were anchored onto the Au NPs/SPCE surface. Then LDL_Apt was immobilized on the surface of MXene-CMCS-Hemin/Au NPs/SPCE to construct the electrochemical aptasensor. When LDL specifically bound with the LDL_Apt to form LDL-LDL_Apt complexes, hindering the electron transfer and reducing the Hemin oxidation current, LDL detection can be achieved via differential pulse voltammetry (DPV). Under optimal circumstances, the changes of Hemin's oxidation current showed a good linear response with LDL concentration in the range of 0.1-4.0 μmol/L with a detection limit of 0.095 μmol/L (S/N = 3). The aptasensor demonstrated good performance with the relative errors of 0.60 % to 6.58 % for the direct detection of LDL in human serum samples, which offers a novel tool for the clinical diagnosis of CVD.

01 May 2025·Diabetes Research and Clinical Practice

Correlation of glycosylated apolipoprotein A1 and glycosylated low-density lipoprotein cholesterol levels with glucose homeostasis and the risk of developing type 2 diabetes mellitus

Article

Author: Zhang, Na ; Gu, Jun-Xu ; Wang, Kun ; Hong, Ting-Ting ; Yin, Yue ; Xu, Lei ; Wang, Chun-Yan ; Qin, Li ; Zhang, Ai-Min ; Su, Ming ; Jia, Mei ; Li, Shan-Shan ; Hu, Nai-Jing

INTRODUCTIONThis study explored the relationship between Glycosylated apolipoprotein A-1 (G-apoA1) and glycosylated low-density lipoprotein cholesterol (G-LDL-C) levels and the risk of developing type 2 diabetes mellitus (T2DM).METHODSThis study included 3,098 patients with prediabetes and T2DM from two centers. Over a 3-year follow-up period, the study analyzed and assessed the risk of developing T2DM based on G-apoA1 and G-LDL-C levels.RESULTSIn patients with T2DM, the levels of G-apoA1 and G-LDL-C were significantly higher than in patients with prediabetes. G-apoA1 and G-LDL-C levels were positively correlated with insulin resistance (HOMA-IR) and negatively correlated with insulin sensitivity (HOMA-IS). During the 3-year follow-up period, 197 patients with prediabetes progressed to T2DM. G-apoA1 and G-LDL-C levels were positively correlated with the risk of developing T2DM. Patients with the highest levels of G-apoA1 [hazard ratio (HR) = 3.452, 95 % confidence interval (95 % CI): 2.120-5.768, p < 0.001] and G-LDL-C (HR: 2.190, 95 % CI: 1.338-3.578, p = 0.002) had a significantly higher risk of developing T2DM compared to those in the lowest quartile.CONCLUSIONG-apoA1 and G-LDL-C levels are inversely related to pancreatic β-cell function, positively related to insulin resistance, and linked with an increased risk of developing T2DM.

01 May 2025·Nutrition, Metabolism and Cardiovascular Diseases

Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis

Review

Author: Cheng, Zhiling ; Yan, Wei ; Zhang, Zhihan ; Jiao, Ning ; Liu, Yang ; Gao, Meiling ; Li, Congxin

AIMSTo evaluate the efficacy and safety of inclisiran in the treatment of hypercholesterolemia.DATE SYNTHESISRandomized controlled trials comparing inclisiran with a placebo were searched until April 2024. Overall, 8 studies involving 4947 patients were included. Inclisiran reduced low-density lipoprotein cholesterol (mean difference [MD]: -46.95 %; 95 % confidence interval [CI]: -53.26 to -40.46; P < 0.05), proprotein convertase subtilisin/kexin type 9 (MD: -70.80 %; 95 % CI: -76.52 to -65.08; P < 0.05), serum total cholesterol (MD: -29.47 %; 95 % CI: -32.56 to -26.39; P < 0.05), non-high-density lipoprotein cholesterol (MD: -40.46 %; 95 % CI: -45.24 to -35.68; P < 0.05), apolipoprotein B (MD: -36.77 %; 95 % CI: -40.94 to -32.61; P < 0.05), and lipoprotein(a) (MD: -20.04 %; 95 % CI: -24.2 to -15.87; P < 0.05) levels but increased high-density lipoprotein cholesterol level (MD: 6.09 %; 95 % CI: 3.63 to 8.55; P < 0.05). The incidences of adverse events, serious adverse events, headache, nasopharyngitis, and muscular adverse reactions were not significantly different between the inclisiran and placebo groups. Inclisiran reduced the incidence of cardiovascular adverse reactions (odds ratio [OR] = 0.79; 95 % CI: 0.65 to 0.96; P = 0.02) and increased the incidence of injection-site reactions (OR = 4.79; 95 % CI: 2.18 to 10.52; P < 0.05).CONCLUSIONInclisiran is effective in treating hypercholesterolemia and has a good safety profile.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Low-density lipoprotein

Basic Info

Related

Analysis